
|Articles|April 1, 2004
New biological treatments show promise for psoriasis
Washington - Biological treatments for psoriasis have largely unraveled the once-secret mechanisms behind this disease. "The biologics including Amevive [alefacept], Raptiva [efalizumab], Embrel [etanercept], and Remicade [infliximab] are scientifically revolutionary and exciting," said John Y. M. Koo, M.D., who spoke about these treatments at the American Academy of Dermatology meeting. Board-certified in dermatology and psychiatry, he is professor and vice chairman of the University of California at San Francisco's department of dermatology.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
First-in-Class Topical GT20029 Demonstrates Promising Phase 2 Efficacy and Tolerability for AGA
2
Highlighting Major Breakthroughs for Atopic Dermatitis and Psoriasis in 2025
3
Considering Biologics and Shared Decision-Making in Moderate to Severe Plaque Psoriasis: Part 2
4
Reviewing the Overarching Umbrella of Psoriatic Disease
5

















